e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mind Medicine (MindMed) Inc. - Common Shares
(NQ:
MNMD
)
13.06
-0.37 (-2.76%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mind Medicine (MindMed) Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year?
↗
December 24, 2025
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.
Via
Stocktwits
Topics
ETFs
MarketBeat’s Top 5 Rated Small-Cap Stocks
↗
December 22, 2025
Via
MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Reports Q3 2025 Earnings Miss Amid Accelerated Clinical Pipeline Spending
↗
November 06, 2025
MindMed reports a wider-than-expected Q3 2025 loss as it accelerates its late-stage clinical trials for MM120, targeting anxiety and depression.
Via
Chartmill
Topics
Earnings
MindMed (MNMD) Q3 2025 Earnings Call Transcript
↗
November 06, 2025
MindMed (MNMD) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For July 31, 2025
↗
July 31, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Why Mind Medicine Stock Is Skyrocketing Today
↗
February 14, 2025
Via
The Motley Fool
Why Mind Medicine Stock Is Soaring Today
↗
January 07, 2025
Via
The Motley Fool
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
↗
October 13, 2025
Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position.
Via
Benzinga
The Insider Report: Panic Never Pays
↗
October 11, 2025
Via
Benzinga
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
↗
August 12, 2025
Mind Medicine stock hasn't beaten the market over the last five years, but what comes next?
Via
The Motley Fool
MindMed (MNMD) Q2 2025 Earnings Call Transcript
↗
August 11, 2025
Via
The Motley Fool
Topics
Earnings
Initial Public Offering
MindMed Reports Strong Q2 2025 Results
↗
August 11, 2025
Via
The Motley Fool
1 Reason to Buy MindMed (MNMD)
↗
August 07, 2025
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company.
Via
The Motley Fool
Topics
Cannabis
Law Enforcement
MindMed (MNMD) Q2 Net Loss Jumps 625%
↗
August 01, 2025
Via
The Motley Fool
Topics
Intellectual Property
Why Mind Medicine Gave Investors a Powerful Buzz in May
↗
June 04, 2025
Via
The Motley Fool
Topics
Law Enforcement
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
↗
May 24, 2025
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
Via
Benzinga
Topics
Government
Why Mind Medicine Stock Vaulted More Than 8% Higher Today
↗
May 20, 2025
Via
The Motley Fool
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
May 20, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Via
Chartmill
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
↗
May 20, 2025
Via
Benzinga
The Future of Healthcare: 10 Predictions For The Next Decade
March 27, 2025
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...
Via
MarketMinute
Topics
Artificial Intelligence
Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday
↗
March 07, 2025
Via
Benzinga
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
↗
March 06, 2025
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.
Via
Stocktwits
Warren Buffett's State of the Market
↗
March 03, 2025
Berkshire's cash hoard is approaching "Dr. Evil" levels.
Via
The Motley Fool
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
↗
February 14, 2025
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
Via
Stocktwits
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
↗
February 12, 2025
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.
Via
Investor's Business Daily
Earnings Scheduled For March 6, 2025
↗
March 06, 2025
Via
Benzinga
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish
↗
January 28, 2025
The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.
Via
Stocktwits
This Westlake Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
January 28, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.